Drug Type Small molecule drug |
Synonyms FPF3400, ASELEND, アセレンド |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (26 Mar 2019), |
Regulation- |
Molecular FormulaH2Na2O3Se |
InChIKeyCQRWCHXOXPSKFW-UHFFFAOYSA-N |
CAS Registry10102-18-8 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D10530 | - | - | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Selenium deficiency | Japan | 26 Mar 2019 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colonic Cancer | Preclinical | United States | 01 May 2009 | |
| Cataract | Preclinical | United States | 01 May 2003 |
Phase 3 | 1,416 | bpcinnkxwg(dxxohspsit) = ufpgjzpmua nwnarzopcj (mfwsekylwm ) | Negative | 11 Jan 2023 | |||
Placebo | bpcinnkxwg(dxxohspsit) = xtnjfgygxd nwnarzopcj (mfwsekylwm ) | ||||||
Phase 3 | 1,089 | fkrlnmcuhd(xsqqvfsdar) = pxufewzyph wpohdpavhb (ghfsllwips, 24.5 - 32.3) | Negative | 01 Sep 2016 | |||
Placebo | fkrlnmcuhd(xsqqvfsdar) = fgczbemwqg wpohdpavhb (ghfsllwips, 21.8 - 29.4) |





